Status:
TERMINATED
Tiotropium/Salmeterol Inhalation Powder in COPD
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Pulmonary Disease, Chronic Obstructive
Eligibility:
All Genders
40+ years
Phase:
PHASE3
Brief Summary
The primary objectives of this study are to assess bronchodilator efficacy as determined by FEV1, the effect on dyspnoea as determined by the BDI/TDI, the effect on health status as determined bt the ...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Main:
- Diagnosis of COPD Post-bronchodilator FEV1\<80% predicted and FEV1/FVC\<70% predicted
- Exclusion criteria:
- Main:
- Significant other diseases then COPD Recent MI Any unstable or life-threatening cardiac arrythmia requiring intervention or change in drug therapy during the past year Hospitalisation for cardiac failure during the past year History of asthma
Exclusion
Key Trial Info
Start Date :
April 15 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 21 2008
Estimated Enrollment :
207 Patients enrolled
Trial Details
Trial ID
NCT00668772
Start Date
April 15 2008
End Date
November 21 2008
Last Update
November 7 2023
Active Locations (64)
Enter a location and click search to find clinical trials sorted by distance.
1
1184.15.01069 Boehringer Ingelheim Investigational Site
Anniston, Alabama, United States
2
1184.15.01071 Boehringer Ingelheim Investigational Site
Mobile, Alabama, United States
3
1184.15.01054 Boehringer Ingelheim Investigational Site
Clearwater, Florida, United States
4
1184.15.01063 Boehringer Ingelheim Investigational Site
Tampa, Florida, United States